Audax Medical, a privately-held medical device company developing osteobiologics, has entered into a comprehensive license agreement with Brown University, acquiring exclusive rights to a proprietary osteobiologic nanotechnology, Arxis.
The Arxis biomaterial consists of organic nanomolecules which have the potential to meet an array of clinical needs.
The implantable material can incorporate varying growth agents that allow its end characteristics to be customised for multiple clinical and regenerative indications throughout the musculoskeletal system.
The Arxis is being developed for use in multiple clinical applications for the regeneration of diseased bone, cartilage, and other soft tissues.
Audax Medical said an additional research agreement has been completed with the Brown University School of Engineering and Department of Orthopedics to further support clinical development of the technology.
Under the terms of the agreement, Audax Medical has obtained exclusive license to a platform of intellectual property and technologies co-developed by Thomas Webster, Brown professor of engineering, addressing the treatment of degenerative bone and soft tissues.
Audax Medical president and CEO Mark Johanson said their partnership with Brown and the University’s world-class scientific team is a significant milestone for Audax Medical.
"The addition of this technology to the company’s product portfolio greatly expands our growing regenerative osteobiologics and soft tissue platforms," Johanson said.